About

Alexandra Lee Strauss, MD, is an Assistant Professor of Clinical Medicine in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Her clinical expertise includes eosinophilic esophagitis, esophageal lichen planus, Barrett's esophagus, achalasia, and GERD. Her research focuses on eosinophilic esophagitis, Barrett's esophagus, and esophageal lichen planus, contributing to the understanding of these conditions through various publications. She completed her undergraduate studies at the Schreyer Honors College at The Pennsylvania State University in 2013 and earned her MD from Sidney Kimmel Medical College of Thomas Jefferson University in 2017.

Research topics

• Internal medicine
• Medicine
• Surgery
• Dermatology
• Intensive care medicine
• General surgery
• Biology
• Gastroenterology

Selected publications

• Conversion to Roux-En-Y Gastric Bypass: a successful means of mitigating reflux after laparoscopic sleeve gastrectomy

  Surgical Endoscopy · 2023 · 20 citations

  1st authorCorresponding
  • Medicine
  • Surgery
  • General surgery
  PublisherDOI

• New Techniques to Screen for Barrett Esophagus.

  PubMed · 2023 · 1 citations

  1st authorCorresponding
  • Medicine
  • Intensive care medicine
  • Surgery

  Barrett esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer that continues to have a poor 5-year survival rate of 20%. Current BE screening strategies aim to detect BE and EAC at early, curable stages, but the majority of patients with EAC are diagnosed outside of BE screening and surveillance programs. Guidelines around the world suggest screening for BE in patients with gastroesophageal reflux disease (GERD) and additional demographic and clinical risk factors using high-definition white-light endoscopy (HDWLE). However, current strategies relying on HDWLE are problematic with high direct and indirect costs, procedural risks, and limitations in patient selection owing to the low sensitivity of GERD as a risk factor for detection of BE. In an effort to address these shortcomings, a variety of other screening strategies are under investigation, including risk prediction algorithms, noninvasive cell collection devices, and other new technologies to make screening more efficient and cost-effective. At this time, only cell collection devices have been integrated into professional guidelines, and clinical implementation of alternatives to endoscopy has lagged. In the future, screening may be personalized using a combination of different screening modalities. This article discusses the current state of BE screening and new approaches that may alter the future of screening.

• Refractory eosinophilic esophagitis: what to do when the patient has not responded to proton pump inhibitors, steroids and diet

  Current Opinion in Gastroenterology · 2022 · 11 citations

  1st authorCorresponding
  • Medicine
  • Gastroenterology
  • Internal medicine

  PURPOSE OF REVIEW: Management for patients with refractory eosinophilic esophagitis (EoE) remains a clinical challenge. This review aims to define refractory EoE, explore rates and reasons for nonresponse, and discuss the evidence that informs the approach to these patients. RECENT FINDINGS: Many patients will fail first-line therapies for EoE. Longer duration of therapy can increase response rates, and initial nonresponders may respond to alternative first-line therapies. There are ongoing clinical trials evaluating novel therapeutics that hold promise for the future of EoE management. Increasingly, there is recognition of the contribution of oesophageal hypervigilance, symptom-specific anxiety, abnormal motility and oesophageal remodelling to ongoing clinical symptoms in patients with EoE. SUMMARY: For refractory EoE, clinicians should first assess for adherence to treatment, adequate dosing and correct administration. Extending initial trials of therapy or switching to an alternative first-line therapy can increase rates of remission. Patients who are refractory to first-line therapy can consider elemental diets, combination therapy or clinical trials of new therapeutic agents. Patients with histologic remission but ongoing symptoms should be evaluated for fibrostenotic disease with EGD, barium esophagram or the functional luminal imaging probe (FLIP) and should be assessed for the possibility of oesophageal hypervigilance.

  DOI

Frequent coauthors

• Gary W. Falk

  7 shared

• Kristle L. Lynch

  5 shared

• Daniel R. Vining

  4 shared

• Joseph Triggs

  Fox Chase Cancer Center

  2 shared

• Noel N. Williams

  University of Pennsylvania

  2 shared

• Jenny M. Shao

  Michigan Medicine

  2 shared

• Shivani U. Thanawala

  University of Pennsylvania

  2 shared

• Amanda B. Muir

  Children's Hospital of Philadelphia

  2 shared

Similar researchers at University of Pennsylvania

• John Q. Trojanowskih-296
• Craig B. Thompsonh-277
• Daniel J Raderh-236
• Carl H. Juneh-218
• M. Celeste Simonh-185